Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.
Serum bactericidal activity was determined against 10 strains each of Pseudomonas aeruginosa and Staphylococcus aureus in serum from volunteers 1 and 6 h after intravenous infusion of cefotaxime, tobramycin, and the combination; or of moxalactam, tobramycin, and the combination. High serum bactericidal activity against P. aeruginosa was found significantly more frequently with moxalactam plus tobramycin than with cefotaxime, moxalactam, and tobramycin alone or with cefotaxime plus tobramycin.
D000900:Anti-Bacterial Agents / Q000097:blood*; D002439:Cefotaxime / Q000008:administration & dosage / Q000097:blood*; D002511:Cephalosporins / Q000097:blood*; D002513:Cephamycins / Q000008:administration & dosage / Q000097:blood*; D003470:Culture Media; D006801:Humans; D007275:Injections, Intravenous; D009070:Moxalactam; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D014031:Tobramycin / Q000008:administration & dosage / Q000097:blood*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D003470:Culture Media; D002439:Cefotaxime; D009070:Moxalactam; D014031:Tobramycin